Alta Fundamental Advisers LLC Sells 65,520 Shares of Indivior PLC $INDV

Alta Fundamental Advisers LLC reduced its holdings in Indivior PLC (NASDAQ:INDV) by 13.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 409,529 shares of the company’s stock after selling 65,520 shares during the period. Indivior comprises approximately 6.7% of Alta Fundamental Advisers LLC’s portfolio, making the stock its 5th largest holding. Alta Fundamental Advisers LLC’s holdings in Indivior were worth $14,694,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of INDV. Goldman Sachs Group Inc. boosted its holdings in shares of Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after buying an additional 1,299,425 shares during the period. Jane Street Group LLC boosted its holdings in shares of Indivior by 2,597.9% in the 1st quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after buying an additional 958,132 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Indivior by 669.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 391,386 shares of the company’s stock valued at $5,769,000 after buying an additional 340,498 shares during the period. Prudential Financial Inc. acquired a new position in shares of Indivior in the 2nd quarter valued at about $207,000. Finally, Walleye Capital LLC acquired a new position in shares of Indivior in the 2nd quarter valued at about $594,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

INDV has been the subject of several research reports. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. Weiss Ratings lowered shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $39.33.

Indivior Stock Up 5.5%

Shares of NASDAQ:INDV opened at $37.39 on Friday. The company has a market cap of $4.56 billion, a PE ratio of 19.17 and a beta of 0.88. The company’s 50-day moving average price is $34.46 and its 200 day moving average price is $34.07. Indivior PLC has a fifty-two week low of $13.42 and a fifty-two week high of $41.00.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. The firm had revenue of $317.00 million for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. As a group, equities analysts anticipate that Indivior PLC will post 4.05 EPS for the current year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.